Sequential SMAD, SHH, and Wnt Signaling for mDA Neuron Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for differentiating neuronal progenitor cells from human stem cells for treating neurodegenerative disorders, such as Parkinson's disease, often result in the growth of unwanted tumors and limited in vivo capability to restore neuronal function.
Innovation Solution
A method involving dual inhibition of SMAD signaling pathways (TGFβ/Activin-Nodal and BMP) combined with activation of Sonic Hedgehog (SHH) and Wnt signaling, along with increased Wnt activator concentration after initial contact, to differentiate human stem cells into midbrain dopamine (mDA) neurons, using agents like BDNF, GDNF, and DAPT, and sorting by CD142 expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If embryonic and somatic stem cells are used for treating neurodegenerative diseases, then cell-based therapy can be provided, but unwanted tumors grow and in vivo capability to restore neuronal function is limited
Solution Approach 1:
The patent applies parameter changes by precisely controlling signaling pathway concentrations and temporal sequences during differentiation. Multiple signaling pathways (SMAD inhibition, SHH activation, Wnt activation) are regulated with specific concentrations and timing to guide stem cells toward mature mDA neuron fate while preventing tumorigenic outcomes
Solution Approach 2:
The differentiation process is segmented into distinct temporal stages with specific signaling pathway activations at each phase. The method divides the complex differentiation into sequential steps: initial SMAD inhibition, followed by SHH and Wnt activation, then BMP withdrawal, and final maturation phases, allowing precise control over cell fate decisions
2Manufacturing precision
If dual inhibition of SMAD signaling with activation of SHH and Wnt signaling is used, then functional mDA cells are produced, but the differentiation process complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-establishing the signaling pathway inhibition/activation conditions before initiating differentiation. SMAD pathways are inhibited and SHH/Wnt pathways are activated in advance to prime stem cells for mDA neuron differentiation, ensuring proper fate specification from the outset
Solution Approach 2:
The differentiation protocol employs dynamic changes in signaling pathway concentrations over time. The method adjusts the levels of SMAD inhibitors, SHH activators, and Wnt activators at different time points to guide cells through distinct differentiation stages, transitioning from progenitor states to mature mDA neurons
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The presently disclosed subject matter provides for in vitro methods of inducing differentiation of human stem cells into midbrain dopamine neurons, and precursors thereof, and cells generated by such methods. The presently disclosed subject matter also provides for uses of such cells for treating neurodegenerative disorders.